BioLife Solutions (NASDAQ: BLFS) and Lannett Co (NYSE:LCI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a summary of recent ratings for BioLife Solutions and Lannett Co, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLife Solutions 0 0 2 0 3.00
Lannett Co 0 3 2 0 2.40

BioLife Solutions presently has a consensus price target of $5.50, indicating a potential upside of 3.97%. Lannett Co has a consensus price target of $21.00, indicating a potential upside of 24.63%. Given Lannett Co’s higher possible upside, analysts clearly believe Lannett Co is more favorable than BioLife Solutions.

Insider and Institutional Ownership

2.6% of BioLife Solutions shares are owned by institutional investors. Comparatively, 87.9% of Lannett Co shares are owned by institutional investors. 37.7% of BioLife Solutions shares are owned by insiders. Comparatively, 15.0% of Lannett Co shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares BioLife Solutions and Lannett Co’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
BioLife Solutions $9.31 million 7.52 -$2.21 million ($0.47) -11.26
Lannett Co $637.34 million 0.99 $245.00 million ($0.03) -561.48

Lannett Co has higher revenue and earnings than BioLife Solutions. Lannett Co is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

BioLife Solutions has a beta of -0.87, meaning that its stock price is 187% less volatile than the S&P 500. Comparatively, Lannett Co has a beta of 2.74, meaning that its stock price is 174% more volatile than the S&P 500.


This table compares BioLife Solutions and Lannett Co’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioLife Solutions -63.71% -64.98% -35.19%
Lannett Co -0.09% 19.80% 6.42%


Lannett Co beats BioLife Solutions on 9 of the 12 factors compared between the two stocks.

About BioLife Solutions

BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.

About Lannett Co

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Receive News & Stock Ratings for BioLife Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions Inc. and related stocks with our FREE daily email newsletter.